IKK Inhibition Increases Bortezomib Effectiveness in Ovarian Cancer

Oncotarget

Volumn 6, Issue 28, 2015, Pages 26347-26358

  Singha, Bipradeb ^a   Gatla, Himavanth Reddy ^a   Phyo, Sai ^a   Patel, Atish ^a   Chen, Zhe Sheng ^a   Vancurova, Ivana ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

bortezomib; IKK; Interleukin 8; Ovarian cancer; Proteasome inhibition

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; BORTEZOMIB; I KAPPA B KINASE; INTERLEUKIN 8; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; TUMOR XENOGRAFT;

EID: 84944472822     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4713     Document Type: Article

References (64)

1. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013; 10:211-224.
2. Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol. 2015; 12:239-245.
3. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9:415-428.
4. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010; 177:1053-1064.
5. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011; 11:719-725.
6. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14:6735-6741.
7. Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS. Chemokines in tumor progression and metastasis. Oncotarget. 2013; 4:2171-2185.
8. Singha B, Gatla HR, Vancurova I. Transcriptional regulation of chemokine expression in ovarian cancer. Biomolecules. 2015; 5:223-243.
9. Xu L, Fidler IJ. Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol Res. 2000; 12:97-106.
10. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ. Blockade of NF?B Signaling Inhibits Angiogenesis and Tumorigenicity of Human Ovarian Cancer Cells by Suppressing Expression of VEGF and IL-8. Cancer Res. 2000; 60:5334-5339.
11. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008; 100:359-372.
12. Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, Meng XY. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 2012; 59:145-155.
13. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006; 57:33-47.
14. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Update. 2008; 11:164-179.
15. Kuhn DJ, Orlowski RZ. The immunoproteasome as a target in hematologic malignancies. Semin Hematol. 2012; 49:258-262.
16. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol. 2005; 23:5943-5949.
17. Ramirez PT, Landen CN Jr, Coleman RL, Milam MR, Levenback C, Johnston TA. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol. 2008; 108:68-71.
18. Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W. Gynecologic Oncology Group. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2009; 115:215-220.
19. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res. 2009; 15:553-560.
20. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010; 77:887-894.
21. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61:3071-3076.
22. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003; 101:1530-1534.
23. Vu HY, Juvekar A, Ghosh C, Ramaswami S, Le DH, Vancurova I. Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of I?B. Arch Biochem Biophys. 2008; 475:156-163.
24. Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I. Bortezomib induces nuclear translocation of I?Ba resulting in gene-specific suppression of NF?B-dependent transcription and induction of apoptosis in CTCL leukemia. Mol Cancer Res. 2011; 9:183-194.
25. Ghosh CC, Ramaswami S, Juvekar A, Vu HY, Galdieri L, Davidson D, Vancurova I. Gene specific repression of proinflammatory cytokines from stimulated human macrophages by nuclear I?Ba. J Immunol. 2010; 185:3685-3693.
26. Manna S, Singha B, Phyo SA, Gatla HR, Chang TP, Sanacora S, Ramaswami S, Vancurova I. Proteasome Inhibition by Bortezomib Increases IL-8 Expression in Androgen-Independent Prostate Cancer Cells: The Role of IKKa. J Immunol. 2013; 191:2837-2846.
27. Singha B, Gatla HR, Manna S, Chang TP, Sanacora S, Poltoratsky V, Vancura A, Vancurova I. Proteasome inhibition increases recruitment of IKKß, S536P-p65 and transcription factor EGR-1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. J Biol Chem. 2014; 289:2687-2700.
28. Chang TP, Poltoratsky V, Vancurova I. Bortezomib inhibits expression of TGF-ß1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T Cell lymphoma cells. J Immunol. 2015; 194:2942-2953.
29. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res. 2000; 6:3719-3728.
30. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih IeM, Roden RB. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res. 2006; 66:3754-3763.
31. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Saito M, Kawagoe J, Takahashi K, Yada-Hashimoto N, Sakata M, Motoyama T, Kurachi H, et al. Inhibition of NF?B increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem. 2004; 279:23477-23485.
32. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J, Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, et al. Inhibition of inhibitor of NF?B phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res. 2004; 10:7645-7654.
33. Levêque D, Carvalho MC, Maloisel F. Clinical pharmacokinetics of bortezomib. In vivo. 2007; 21:273-278.
34. Nomiyama H, Osada N, Yoshie O. The evolution of mammalian chemokine genes. Cytokine and Growth Factor Rev. 2010; 21:253-262.
35. Buss H, Dörrie A, Schmitz ML, Hoffmann E, Resch K, Kracht M. Constitutive and IL-1-inducible phosphorylation of p65 NFkB at serine 536 is mediated by multiple protein kinases including IkB kinase (IKK)-a, IKKß, IKKe, TRAF family member-associated (TANK)-binding kinase 1 , and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated IL-8 transcription. J Biol Chem. 2004; 279:55633-55643.
36. Sasaki CY, Barberi TJ, Ghosh P, Longo DL. Phosphorylation of RelA/p65 on serine 536 defines an I?B a-independent NF?B pathway. J Biol Chem. 2005; 280:34538-34547.
37. Saccani S, Marazzi I, Beg AA, Natoli G. Degradation of promoter-bound p65/RelA is essential for the prompt termination of the NF?B response. J Exp Med. 2004; 200:107-113.
38. Tanaka T, Grusby MJ, Kaisho T. PDLIM2-mediated termination of transcription factor NF?B activation by intranuclear sequestration and degradation of the p65 subunit. Nature Immunol. 2007; 8:584-591.
39. Geng H, Wittwer T, Dittrich-Breiholz O, Kracht M, Schmitz ML. Phosphorylation of NF?B p65 at Ser468 controls its COMMD1-dependent ubiquitination and target gene-specific proteasomal elimination. EMBO Rep. 2009; 10:381-386.
40. Karin M. How NF?B is activated: the role of the I?B kinase (IKK) complex. Oncogene. 1999; 18:6867-6874.
41. Kanarek N, Ben-Neriah Y. Regulation of NF-?B by ubiquitination and degradation of the I?Bs. Immunol Rev. 2012; 246:77-94.
42. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi N, Richardson PG, Carrasco RD, Anderson KC. Bortezomib induces canonical NF?B activation in multiple myeloma cells. Blood. 2009; 114:1046-1052.
43. Relic B, Benoit V, Franchimont N, Ribbens C, Kaiser MJ, Gillet P, Merville MP, Bours V, Malaise MG. 15-deoxy-delta12, 14 prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts. J Biol Chem. 2004; 279:22399-22403.
44. Hu X, Janssen WE, Moscinski LC, Bryington M, Dangsupa A, Rezai-Zadeh N, Babbin BA, Zuckerman KS. An I?Ba inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF?B-independent mechanism. Cancer Res. 2001; 61:6290-6296.
45. Lee LF, Li G, Templeton DJ, Ting JP. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem. 1998; 273:28253-28260.
46. Xu L, Pathak PS, Fukumura D. Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of IL-8 in human ovarian carcinoma cells. Clin Cancer Res. 2004; 10:701-707.
47. Yin J, Yu C, Yang Z, He JL, Chen WJ, Liu HZ, Li WM, Liu HT, Wang YX. Tetramethylpyrazine inhibits migration of SKOV3 human ovarian carcinoma cells and decreases the expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling pathways. Oncol Rep. 2011; 26:671-679.
48. Jazirehi AR, Economou JS. Proteasome inhibition blocks NF?B and ERK1/2 pathways, restores antigen expression and sensitizes resistant human melanoma to TCR-engineered CTLs. Mol Cancer Ther. 2012; 11:1332-1341.
49. Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G, Papandreou CN, Liakos P. Bortezomib represses HIF-1a protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med (Berl). 2012; 90:45-54.
50. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T, Mor G. Regulation of IKKß by miR-199a affects NF?B activity in ovarian cancer cells. Oncogene. 2008; 27:4712-4723.
51. Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF?B signaling by inhibitor of NF?B kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 2010; 70:4005-4014.
52. Kinose Y, Sawada K, Makino H, Ogura T, Mizuno T, Suzuki N, Fujikawa T, Morii E, Nakamura K, Sawada I, Toda A, Hashimoto K, Isobe A, et al. IKKß regulates VEGF expression and is a potential therapeutic target for ovarian cancer as an antiangiogenic treatment. Mol Cancer Ther. 2015; 14:909-919.
53. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998; 351:104-107.
54. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer. 2008; 98:1781-1783.
55. Murphy MA, Trabert B, Yang HP, Park Y, Brinton LA, Hartge P, Sherman ME, Hollenbeck A, Wentzensen N. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control. 2012; 23:1839-1852.
56. Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ. Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer)Risch HA, Rossing MA, Doherty JA, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014; 106:djt431.
57. Zerbini LF, Tamura RE, Correa RG, Czibere A, Cordeiro J, Bhasin M, Simabuco FM, Wang Y, Gu X, Li L, Sarkar D, Zhou JR, Fisher PB, et al. Combinatorial effect of non-steroidal anti-inflammatory drugs and NF?B inhibitors in ovarian cancer therapy. PLoS One. 2011; 6:e24285.
58. Valle BL, D'Souza T, Becker KG, Wood WH 3rd, Zhang Y, Wersto RP, Morin PJ. Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells. PLoS One. 2013; 8:e61836.
59. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I?B kinease-beta. Nature. 1998; 396:77-80.
60. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF?B activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004; 23:9247-9258.
61. Huang Y, Fan W. I?B kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharmacol. 2002; 61:105-113.
62. Yang YI, Lee KT, Park HJ, Kim TJ, Choi YS, Shih IeM, Choi JH. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NF?B pathway. Carcinogenesis. 2012; 33:2488-2498.
63. Kathawala RJ, Sodani K, Chen K, Patel A, Abuznait AH, Anreddy N, Sun YL, Kaddoumi A, Ashby CR Jr, Chen ZS. Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study. Mol Cancer Ther. 2014; 13:714-723.
64. Kathawala RJ, Wei L, Anreddy N, Chen K, Patel A, Alqahtani S, Zhang YK, Wang YJ, Sodani K, Kaddoumi A, Ashby CR Jr, Chen ZS. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget. 2015; 6:510-521.